Canaccord Genuity Group Issues Pessimistic Forecast for Voyager Therapeutics (NASDAQ:VYGR) Stock Price

Voyager Therapeutics (NASDAQ:VYGR) had its target price dropped by analysts at Canaccord Genuity Group from $14.00 to $12.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 197.69% from the company’s current price.

VYGR has been the subject of several other research reports. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the company an “overweight” rating in a report on Wednesday. Citigroup began coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday. Finally, Wedbush reiterated an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Voyager Therapeutics has an average rating of “Buy” and a consensus target price of $14.86.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR traded down $0.03 during trading on Thursday, reaching $4.03. The stock had a trading volume of 136,646 shares, compared to its average volume of 369,855. Voyager Therapeutics has a 1-year low of $3.56 and a 1-year high of $10.66. The stock has a market cap of $220.20 million, a PE ratio of 5.68 and a beta of 0.99. The business has a fifty day moving average price of $4.91 and a 200-day moving average price of $5.86.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The business had revenue of $4.39 million for the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period last year, the firm earned $1.25 EPS. Sell-side analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Activity at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at $634,653.20. This trade represents a 5.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 10,778 shares of company stock worth $58,548 over the last 90 days. Company insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

A number of large investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC acquired a new stake in Voyager Therapeutics during the fourth quarter worth approximately $29,000. Tower Research Capital LLC TRC boosted its holdings in Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock valued at $31,000 after acquiring an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management grew its position in Voyager Therapeutics by 71.1% during the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after acquiring an additional 2,444 shares during the period. Oxford Asset Management LLP acquired a new stake in Voyager Therapeutics during the fourth quarter worth about $60,000. Finally, Intech Investment Management LLC purchased a new position in shares of Voyager Therapeutics in the 3rd quarter worth about $74,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.